Fundz

Coultreon Biopharma Appoints Prista Charuworn as Chief Medical Officer

PRIVATEAug 18, 2026
New to company · from Zai Lab“Immediately prior to joining Coultreon, Dr. Charuworn was the Global Head of Neuroscience and Immunology at Zai Lab.”

Position

Chief Medical Officer

Company

Coultreon Biopharma

Prista Charuworn
BiotechnologyHealth CareTherapeutics

Description

Coultreon Biopharma announced the appointment of Prista Charuworn, MD, as Chief Medical Officer. Dr. Charuworn brings extensive immunology drug development experience to accelerate the clinical development of Coultreon's first-in-class SIK3 inhibitor COL-5671.

Quick answer

Coultreon Biopharma Appoints Prista Charuworn as Chief Medical Officer (August 18, 2026).

Who is the new Chief Medical Officer at Coultreon Biopharma?
Coultreon Biopharma named Prista Charuworn Chief Medical Officer, announced August 18, 2026.
What did Coultreon Biopharma announce on August 18, 2026?
Coultreon Biopharma announced the appointment of Prista Charuworn, MD, as Chief Medical Officer. Dr. Charuworn brings extensive immunology drug development experience to accelerate the clinical development of Coultreon's first-in-class SIK3 inhibitor COL-5671.
Where did Prista Charuworn work before joining Coultreon Biopharma?
Prista Charuworn joins from Zai Lab.
What does Coultreon Biopharma do?
Coultreon Biopharma, formerly known as Onco3R Therapeutics, is a biotechnology company based in Leuven, Belgium.
Which similar companies made leadership changes around the same time?
Nurix Therapeutics (August 21, 2026), Neumora (August 14, 2026), Olema Oncology (August 14, 2026) and Olema Oncology, Inc. (August 13, 2026) also announced leadership changes within 45 days of Coultreon Biopharma.

Source: Fundz verified event record.

Other recent leadership changes in Therapeutics and Biotechnology

Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.

Who to call at Coultreon Biopharma, and when

A new leader at Coultreon Biopharma brings new priorities and often new vendors. The first weeks are when they listen.

  • An alert the day Coultreon Biopharma raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Coultreon Biopharma, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Coultreon Biopharma. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Coultreon Biopharma

About

Coultreon Biopharma, formerly known as Onco3R Therapeutics, is a biotechnology company based in Leuven, Belgium. The company develops therapies targeting clinically-validated pathways across immunology and metabolic diseases. With a focus on salt-inducible kinase (SIK) biology, Coultreon aims to deliver broader and more durable disease control through innovative drug discovery. Their lead program, COL-5671, is a highly selective SIK3 inhibitor currently in clinical development for autoimmune diseases.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Coultreon Biopharma changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Fabrice
Senior decision-maker at this company
••••••••@••••••••

See Fabrice's verified email →

Evelien
Senior decision-maker at this company
••••••••@••••••••

See Evelien's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Coultreon Biopharma's next move

Learn about Strategic plan

Coultreon Biopharma changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.